Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Dose Escalation and Expansion Study of PF-07265028 ± Sasanlimab in Advanced Solid Tumors
jRCT2031210676Phase 1Completed
- Sponsor
- Pfizer
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of pf-07265028 and sasanlimab in Nonhematologic neoplasms, gastric cancer (GC), esophagogastric junction cancer and 3 more (2 arms), sponsored by Pfizer. Primary endpoints: Dose-limiting toxicities in Dose Escalation (Part 1), Adverse events and 2 more. Started Mar 2022; status: completed.
02
Drugs
pf-07265028sasanlimab
03
Conditions
Nonhematologic neoplasmsgastric cancer (GC)esophagogastric junction cancerhead and neck squamous cell carcinoma (HNSCC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on jRCT2031210676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210676.